BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trabedersen regulatory update

Antisense said FDA and the EC granted Orphan Drug designation for trabedersen to treat pancreatic carcinoma....

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >